Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKAB1 | Q9Y478 | 12/20 | 1.00 |
| ▸ | KDR | P35968 | 12/20 | 1.00 |
| ▸ | PRKAB2 | O43741 | 11/20 | 1.00 |
| ▸ | PRKAG1 | P54619 | 11/20 | 1.00 |
| ▸ | PRKAA2 | P54646 | 11/20 | 1.00 |
| ▸ | PRKAA1 | Q13131 | 11/20 | 1.00 |
| ▸ | PRKAG3 | Q9UGI9 | 11/20 | 1.00 |
| ▸ | PRKAG2 | Q9UGJ0 | 11/20 | 1.00 |
| ▸ | FLT1 | P17948 | 10/20 | 1.00 |
| ▸ | LCK | P06239 | 6/20 | 1.00 |
| ▸ | SRC | P12931 | 6/20 | 1.00 |
| ▸ | EPHA2 | P29317 | 6/20 | 1.00 |
| ▸ | RPS6KA1 | Q15418 | 6/20 | 1.00 |
| ▸ | MKNK1 | Q9BUB5 | 6/20 | 1.00 |
| ▸ | BMP4 | P12644 | 6/20 | 1.00 |
| ▸ | FLT4 | P35916 | 5/20 | 1.00 |
| ▸ | FLT3 | P36888 | 3/20 | 1.00 |
| ▸ | ACVR1 | Q04771 | 3/20 | 0.83 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.81 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15996328 | 0.91 | KDR (1.00) | PRKAB1KDRPRKAB2PRKAG1PRKAA2 | |
| SCHEMBL15996327 | 0.90 | KDR (0.81) | PRKAB1KDRPRKAB2PRKAG1PRKAA2 | |
| Dorsomorphin SCHEMBL463155 | 0.90 | KDR (1.00) | PRKAB1KDRPRKAB2PRKAG1PRKAA2 | |
| Dorsomorphin SCHEMBL17845800 | 0.89 | KDR (0.98) | PRKAB1KDRPRKAB2PRKAG1PRKAA2 | |
| Dorsomorphin SCHEMBL2119244 | 0.89 | KDR (0.98) | PRKAB1KDRPRKAB2PRKAG1PRKAA2 | |
| SCHEMBL2059672 | 0.89 | BMP4 (1.00) | PRKAB1KDRPRKAB2PRKAG1PRKAA2 | |
| SCHEMBL31087251 | 0.88 | KDR (0.81) | PRKAB1KDRPRKAB2PRKAG1PRKAA2 | |
| SCHEMBL7612865 | 0.87 | KDR (1.00) | PRKAB1KDRPRKAB2PRKAG1PRKAA2 | |
| Dorsomorphin SCHEMBL26968137 | 0.87 | KDR (0.94) | PRKAB1KDRPRKAB2PRKAG1PRKAA2 | |
| SCHEMBL27218135 | 0.85 | PRKAB1 (1.00) | PRKAB1KDRPRKAB2PRKAG1PRKAA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230398118-A1 | METHODS OF TREATING CARDIOVASCULAR-RELATED DISEASE | KEROS THERAPEUTICS, INC. | 2023-12-14 | — | — | US | disclosed |
| US-20230398118-A1 | METHODS OF TREATING CARDIOVASCULAR-RELATED DISEASE | KEROS THERAPEUTICS, INC. | 2023-12-14 | — | — | US | disclosed |
| US-20230372390-A1 | METHODS OF TREATING LYMPHOPENIA | KEROS THERAPEUTICS, INC. | 2023-11-23 | — | — | US | disclosed |
| US-20230372390-A1 | METHODS OF TREATING LYMPHOPENIA | KEROS THERAPEUTICS, INC. | 2023-11-23 | — | — | US | disclosed |
| US-20220401445-A1 | METHODS OF USING ALK2 INHIBITORS | KEROS THERAPEUTICS, INC. | 2022-12-22 | — | — | US | disclosed |
| US-11318103-B2 | Treating soft tissue via controlled drug release | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2022-05-03 | — | — | US | disclosed |
| WO-2020168290-A1 | N-ARYL BENZENESULFONAMIDES FOR USE IN TREATING CANCERS, BACTERIAL DISEASES, METABOLIC DISEASES, AND TRAUMATIC BRAIN INJURY | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2020-08-20 | — | — | WO | disclosed |
| US-20190142758-A1 | TREATING SOFT TISSUE VIA CONTROLLED DRUG RELEASE | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2019-05-16 | — | — | US | disclosed |
| US-10179111-B2 | Treating soft tissue via controlled drug release | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2019-01-15 | — | — | US | disclosed |
| US-20170014349-A1 | TREATING SOFT TISSUE VIA CONTROLLED DRUG RELEASE | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2017-01-19 | — | — | US | disclosed |
| US-8507501-B2 | Inhibitors of the BMP signaling pathway | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2013-08-13 | — | — | US | disclosed |
| US-8507501-B2 | Inhibitors of the BMP signaling pathway | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2013-08-13 | — | — | US | disclosed |
| US-8507501-B2 | Inhibitors of the BMP signaling pathway | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2013-08-13 | — | — | US | disclosed |
| WO-2012100229-A2 | COMPOSITIONS AND METHODS FOR CARDIOVASCULAR DISEASE | THE GENERAL HOSPITAL CORPORATION (US) | 2012-07-26 | — | — | WO | disclosed |
| US-20110053930-A1 | INHIBITORS OF THE BMP SIGNALING PATHWAY | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2011-03-03 | — | — | US | disclosed |
| US-20110053930-A1 | INHIBITORS OF THE BMP SIGNALING PATHWAY | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2011-03-03 | — | — | US | disclosed |
| US-20110053930-A1 | INHIBITORS OF THE BMP SIGNALING PATHWAY | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2011-03-03 | — | — | US | disclosed |
| EP-2265603-A1 | INHIBITORS OF THE BMP SIGNALING PATHWAY | The General Hospital Corporation (US) | 2010-12-29 | — | — | EP | disclosed |
| WO-2009114180-A1 | INHIBITORS OF THE BMP SIGNALING PATHWAY | THE GENERAL HOSPITAL CORPORATION (US) | 2009-09-17 | — | — | WO | disclosed |
| WO-2009114180-A1 | INHIBITORS OF THE BMP SIGNALING PATHWAY | THE GENERAL HOSPITAL CORPORATION (US) | 2009-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220401445-A1 | METHODS OF USING ALK2 INHIBITORS | ALK, ACVR2A, ACVR1 | PRKAB1 1439/4885KDR 46/4885PRKAB2 632/4885 |
| US-10179111-B2 | Treating soft tissue via controlled drug release | BMP2, BMP1, BMP6 | PRKAB1 3381/4885KDR 203/4885PRKAB2 3411/4885 |
| US-20110053930-A1 | INHIBITORS OF THE BMP SIGNALING PATHWAY | BMP1, BMP2K, BMP2 | PRKAB1 1836/4885KDR 260/4885PRKAB2 1976/4885 |
| US-20170014349-A1 | TREATING SOFT TISSUE VIA CONTROLLED DRUG RELEASE | BMP2, BMP1, BMP6 | PRKAB1 3381/4885KDR 203/4885PRKAB2 3411/4885 |
| US-20230398118-A1 | METHODS OF TREATING CARDIOVASCULAR-RELATED DISEASE | BMPR2, BMP1, BMP2 | PRKAB1 1575/4885KDR 138/4885PRKAB2 823/4885 |
| US-11318103-B2 | Treating soft tissue via controlled drug release | BMP2, BMP1, BMP6 | PRKAB1 3381/4885KDR 203/4885PRKAB2 3411/4885 |
| US-20190142758-A1 | TREATING SOFT TISSUE VIA CONTROLLED DRUG RELEASE | BMP2, BMP1, BMP6 | PRKAB1 3381/4885KDR 203/4885PRKAB2 3411/4885 |
| US-20230372390-A1 | METHODS OF TREATING LYMPHOPENIA | HAMP, BMPR2, BMP2 | PRKAB1 2841/4885KDR 1564/4885PRKAB2 1864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.